Oritavancin, sold under the brand name Orbactiv (by Melinta Therapeutics) among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections.

2025年3月1日 · Oritavancin injection is used to treat acute bacterial skin and skin structure infections (ABSSSI). Oritavancin belongs to the group of medicines known as antibiotics. It works by killing bacteria or preventing their growth. Oritavancin …

2014年6月5日 · Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and prolonged half-life allow for single-dose treatment.

2024年6月5日 · What is oritavancin? Oritavancin is an antibiotic that is used to treat severe skin infections caused by bacteria. Oritavancin may also be used for purposes not listed in this medication guide.

Both KIMYRSA ® and ORBACTIV ® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA ...

ORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and -resistant [MRSA ...

2007年10月21日 · Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection.

Oritavancin is a new-generation lipoglycopeptide indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible organisms, including Staphylococcus aureus (methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] strains), certain Streptococcus species, and Enterococcus ...

Oritavancin is a semisynthetic lipoglycopeptide antibiotic that was recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults.